Articles

Elsevier,

The Lancet Global Health, Volume 9, April 2021

This Comment supports SDGs 3 and 10 by highlighting the need to centre race in the work of the global health community. The authors call on colleagues to meaningully engage with critical race theory, a transdisciplinary intellectual movement to understand and disrupt systemic racism.
Elsevier, JTO Clinical and Research Reports, Volume 2, April 2021
Introduction: Estrogen receptors (ER) (ERα, ERβ) and aromatase (key enzyme for estrogen synthesis) are expressed in most human NSCLCs. High intratumoral estrogen levels and elevated aromatase expression in NSCLC predict poor outcome. This open-label, phase 1b, single-center study evaluated the safety and tolerability of escalating doses of the aromatase inhibitor, exemestane, in combination with carboplatin and pemetrexed in postmenopausal women with stage IV nonsquamous NSCLC.
Elsevier, Progress in Disaster Science, Volume 10, April 2021
The COVID-19 pandemic has uncovered and intensified existing societal inequalities. People on the move and residents of urban slums and informal settlements are among some of the most affected groups in the Global South. Given the current living conditions of migrants, the WHO guidelines on how to prevent COVID-19 (such as handwashing, physical distancing and working from home) are challenging to nearly impossible in informal settlements.
Elsevier,

The Lancet Global Health, Volume 9, April 2021

This Comment article supports SDGs 3, 10, and 17 by highlighting the need for full inclusivity and representation, and the involvement of a diverse range of stakeholders and voices, in order to successfully design solutions to global health problems and to reform the systems that are exacerbating global health inequities.
Elsevier,

EClinicalMedicine, Volume 34, April 2021

" This Comment article supports SDG 3 and 10 by proposing that future studies exploring the link between racism and health inequalities are designed with more theoretically informed research questions, whose findings can more readily help tackle existing problems. Suggested areas for further research include the impact of neighourhood desegregation, increased racial diversity in labour markets, and reduced mass incarceration in diminishing racial health inequalities.
Elsevier,

The Lancet Digital Health, Volume 3, April 2021

Data-driven digital health technologies have the power to transform health care. If these tools could be sustainably delivered at scale, they might have the potential to provide everyone, everywhere, with equitable access to expert-level care, narrowing the global health and wellbeing gap. Conversely, it is highly possible that these transformative technologies could exacerbate existing health-care inequalities instead.

Elsevier,

EClinicalMedicine, Volume 34, April 2021

This Comment supports SDGs 3 and 10 by highlighting inequities in palliative care between racial groups, including differences in the use of palliative care services, symptom control, and the documentation and implementation of people's end of life wishes.
Elsevier,

EClinicalMedicine, Volume 34, April 2021

This Research paper supports SDGs 3 and 10 by assessing ethnic differences in SARS-CoV-2 seropositivity among hospital workers. The findings showed that Black people had more than double the likelihood of SARS-CoV-2 seropositivity compared with White people, independent of age, sex, socioeconomic factors, and hospital role.
Elsevier,

The Lancet Digital Health, Volume 3, April 2021

This Article supprts SDGs 3 and 10 by assessing the performance of four severity scoring systems used for case-mix determination and benchmarking in intensive care units to identify possible ethnicity-based bias. The study found systemic differences in calibration across ethnicities.
Elsevier, The Lancet Global Health, Volume 9, April 2021
Background: Increasing access to hepatitis C virus (HCV) care and treatment will require simplified service delivery models. We aimed to evaluate the effects of decentralisation and integration of testing, care, and treatment with harm-reduction and other services, and task-shifting to non-specialists on outcomes across the HCV care continuum.

Pages